<SEC-DOCUMENT>0001129928-12-000074.txt : 20121213
<SEC-HEADER>0001129928-12-000074.hdr.sgml : 20121213
<ACCEPTANCE-DATETIME>20121213164726
ACCESSION NUMBER:		0001129928-12-000074
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121213
FILED AS OF DATE:		20121213
DATE AS OF CHANGE:		20121213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		121262582

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;December 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release Dated December 13, 2012:&#160;&#160;Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN&#174; Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;December 13, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="onclogo.jpg" alt=""><br>
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN&#174; Data for First Endpoint in&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Randomized Phase III Study in Head and Neck Cancers</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, December 13, 2012 ---</font> Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221; or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-na&#239;ve head and neck cancers (REO 018).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans (typically performed at six weeks post-first treatment) of all patients enrolled in the study. The analysis was designed to assess early differences in response between loco-regional tumours and metastatic tumours, as classified and observed by the investigators. This is the first, and to this point only, endpoint to be un-blinded for this study.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The first analysis compared the relative percentages of patients in the test and control arms with tumours that had either stabilized or exhibited shrinkage. For the purposes of this endpoint, the definition of tumour stabilization was restricted to zero percent growth only. Of the 105 total patients with evaluable metastatic tumours, 86 percent (n=50) of those in the test arm of the study exhibited tumour stabilization or shrinkage, compared with 67 percent of patients (n=55) in the control arm. This was statistically significant, with a p-value of 0.025.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The second analysis examined the magnitude of tumour response on a per patient basis using a comparison of percentage tumour shrinkage at six weeks in each patient with evaluable metastatic tumours. This analysis showed that REOLYSIN in combination with carboplatin and paclitaxel was statistically significantly better than carboplatin and paclitaxel alone at stabilizing or shrinking metastatic tumours, yielding a p-value of 0.03.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At the six week point, there is a numeric trend in favour of the test group towards differing activity between the test and control groups in patients with loco-regional tumours.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In an intragroup analysis of the test arm, an improvement in the percentage of patients&#8217; metastatic tumours over loco-regional tumours was noted (p=0.083) and an improvement of magnitude of response in metastatic tumours over loco-regional tumours was also noted (p=0.13). By contrast, in an intragroup analysis of the control arm, no statistical differences were noted between the responses of patients with evaluable metastatic tumours and patients with evaluable loco-regional tumours.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;To the best of our knowledge, this is the first successful double-blinded randomized data from a clinical study using an intravenously-administered oncolytic virus. We are delighted to have obtained statistically significant data for REOLYSIN in a randomized clinical setting,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;We continue to await the data for the other endpoints of this study, to which all parties still remain blinded at this point.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conference Call Details</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Thursday, December 13<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2012 at 6:00 a.m. MT (8:00 a.m. ET) to discuss in more depth the Company's Phase III study in head and neck cancers. To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live audio webcast will also be available at the following link: <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.newswire.ca/en/webcast/detail/1087657/1184933</font> or through the Company's website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com/presentations</font>. Please connect at least 10 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com/presentations</font> and will also be available by telephone through December 20<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2012. To access the telephone replay, dial 1-416-849-0833 or 1-855-859-2056 and enter reservation number 81080621 followed by the number sign.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The Company also intends to post the prepared remarks from the call to its corporate website following the call.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company's expectations related to the Phase III head and neck cancers trial of REOLYSIN in combination with carboplatin and paclitaxel, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: #ffffff 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta&#160;&#160;T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
</td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: #ffffff 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DGI, LLC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tom Caden</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">398 West Broadway, 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">tcaden@dgicomm.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^
M****`"BBB@`HKAOB)\2?`_PG\+:GXX^(_BK0/!?A#18&N-4\0^)=4M-(TNS0
M<*KW5[+%&\\[$0VMM$9+FZN'CM[>*2615K\"?VE_^#@+X7^%+F_\-_LS?#F\
M^)^H6YDMT\>>-YKKPMX*,X8*+G2_#\2?\)5XAL\A0HO7\)/.'#VCSHJL_@YO
MQ)D^104\SQE*AS1YH44^?$3CIK&EHW:^OJC6E1J5I<M.+EW?1?\`#G]%]%?P
M^ZK_`,%._P#@J7^TKJMSI_PSU_QE"D[L/^$6^`'PM2=K42D%(HM2L-'\1^+H
MHE#1HLD^O/<;AM\QY'I\7@#_`(+>:^HU(7'[>48G`<*_C_XE^'R%;)'_`!+I
M?$FEF'Z?9(F'\2C*Y^1_XB7AZMI8#AW/\?2_Y^TL+:'2UG[U[W?;;[NCZE)?
M%5I+M[U^WY7^[[C^W^BOX<[KXA_\%I?@2IU;6=0_;/TZRLQYL^H^+=(\9_$+
M0H8DSN:ZG\2:?XHT=H@$9I#<RDA2690L1(]P^"__``7Q_:F\!WUOI7QP\$^"
M_C!H]N_DZC/'8'X=>.$8,L4Q%YI4$_AIS#B1A:3>$X9Y70Q27<:%YE=#Q.RA
M58TLSR_-<H;WJ8O#/V4;6O?E_>2W7\.E-*_O-:-OZA4E_#J4IVW]ZUMO5/K]
MQ_8Y17YS_LF?\%0?V6/VNGL]`\(>*)?!/Q)N44'X8_$#[)HGB.[G"$S)X=NQ
M<S:+XKC0I(PCT34)]3CM@+B^TRQ7<B_HQ7WV!S'!9GAX8K`8FEBL/-7C5I2Y
MHOOV:MYI''.$Z<G"<7&2W3_SZA1117:2%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?$W[;7[<GPG_8C^&@\9
M^/IO[9\5:VEU:?#[X<Z7=11Z_P",M7@1`^QG60:9H&FF:&;6]?GAEMK&%H[>
MWBOM6NM/TR\]M_:'^//@?]FCX0>-OC1\1;O[-X7\%Z//?RP0O&-0UC5)&2VT
M;P[I,4A59M5U[4Y[;3;%&98DFG$UR\5K'--'_%5X0\,_M#_\%?OVR[^_U6_G
ML8+^9=0\1:SLN+OPO\&_A597VVRTC2H&9`T\<4QT[1[`-#<>)?$5S<:SJCQ^
M?K>I0_"\7\45\J6%RS*:/UO/,SE[+"4(^][!/EM7K1MI;F]R+:4K2?,K'7A:
M$:SG.J[4J4>>?GV6^BON]?3<DUCQ!^W'_P`%?OCE_9UA#>:WI^FW9N;70;.X
MN=$^#?P>T.ZG>".ZU"X<S6L%SY#2(^HW0U/Q;XA>&>WL5N@L-A!_0/\`LF_\
M$0?V9?@G8Z9X@^-4(_:!^(T*Q3W(\002V?PWTR]`5GATOP<DJC6X8V#QM<^+
MIM2AOE`NAH^G2L(X_P!.OV</V;?A3^RS\,-&^%'PBT"#1?#^F11R7]\\<3ZY
MXGUHQ(E[XD\3:BD<;ZGK.HLBM-,RI!;PK#8:=;V>G6MK:0>^5RY#P#@\,WF6
M?MYSG=>;K5JN*;JT*,I+6G"C)NE5L]'.I![>ZH]:JXZ4TZ>'Y:5%6Y>6-F[V
MW[6MWO=LY_PSX5\-^#=)M]!\*>']$\,Z):(L=IH_A[2K'1M,M8U4(L=O8Z=!
M;6L**JJH6.)<`=3VZ"BBOT&G"-."A",816T8148KT2V.(*^5OCS^Q3^S%^TO
MI]S:?&#X1>$/$NH7$;I'XJMM.30O&MBSY(FL?%VB&QU^-HW/FK!-?3V4S@+=
M6MQ#NB;ZIHK+$87#XN#I8FA1KTY?%"M2IU8O;I.,NW3?J4I2C\+:]#^//]MC
M_@B1\5?@1%??%3]EK6-?^*_@?1Y#JUQX1=1%\6?",5JYNUO](?25M8?&-OIY
MACG,VD0:?XD@$:-#HFH"U:['K'_!-?\`X+,ZYX9U/0_@-^V+KD^J^'Y[BWT'
MPE\:-89AK7ABZ686MOH_Q,ED7SM3T@RN+5/%LX&JZ+(JGQ(UW8"[U?2OZM*_
MG-_X*[_\$L=)\=Z'XD_:D_9V\/1V/Q'TFVOO$'Q6\`Z+:%;?Q_I=M$9M1\6Z
M!I]N-D/C/354WNKV-M"R^++);RY2"7Q./^)Y^89QPOC>&:\L_P"$9S@H:X_)
M6G/#8G#Z<[ITKI7BFW:VB>C/0HXF.(4</BO>3TA53M.&U[.S7O>[>_9>9_11
M97EO?VT-W:RQ7%M<PQ7%M<6\JSV]Q;SKYD$\$R9CFBFB*2QRQL\;QNKH[*0Q
MM5_,7_P1%_X*&7NHS6/[&7QBUJ2]O(K29_@3XEU:Z9[B6TTZVDN+WX97MY,3
M).]E903:AX.>9G=+"VO]`1UBM-!LJ_ITK[OA[/L+Q%EE',L+[JG^[KT7*\\/
MB8V]I1EHK\MU:5E>^R:.*M2E1J2IRZ:Q?\T'\,K=+_/U"BBBO<,@HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***I:CJ%KI=
ME=ZA>S);V=E:W-Y=3R':D-O:0O//*YP<)'$CN[9X`X!S0W9-]M0/Y)_^"]O[
M4][XV^+?A/\`92\+W\TGASX806'BWQW:VDCE=5^(?B6R$F@Z7<1Q_P#'P/#O
MA/4+:YMPF[=?>+;B(J)].C9/W$_X)A?L<Z?^R#^S-X<T34]/AB^*WQ"MM/\`
M''Q7U%XH_M::WJ%FLVF^$_-P7^P^"]/G&D1PAV@?5?[8U&$*FH[%_E__`&,-
M%N_VY/\`@J?HOC3Q5`VHZ/K_`,7?&/QW\307>^XMXM#\+WNJ>*]#T:X1PX;3
MOMT/ACPPELP$:6,L=LNQ%(D_NAK\IX*H1S_.,[XOQ'ON>+J8#*[_`/+G#46U
M*I&+_AU'>*C)7<??5WT]#%2]E2I8:*M[O/571N7+RKY6EHWL]D%%%%?JQYX4
M444`%%%%`!364."K`$$$$,`00>H(/4'C([XIU%`'\1__``5;_9AU/]B7]KW0
M/B]\(?M'A3PA\2-77XI_#J^TB$6<'@_XA^']5M=2\3:#IJPXCMHM.UC[!XCT
MJU&VTATS6TTB&!K339XU_K7_`&1/V@-)_:@_9W^%WQOTM8+>7QGX:M9M?TVW
M<M%H_BW3))='\7:.@8M(L6G^([#4H+1I?GN-/%I>8*7",WQ-_P`%K?@E:?%O
M]AKQKXBBM%G\0_!;6-%^)^BS+&#<)96=P-`\60"4(9$M#X6US4]2G1'0/=:3
M83,<V\>/B_\`X-X/B_/JOPR^//P/O[MI%\%>*O#?Q"\/0R.28[#QOIMWHNNV
MD'41V]E?>$=.O9%!V&?7))`/,DD4?D^5TUPWQYB<HA:&6<0X=XS#T(NU.GBH
M/VD7!7?VZ5>EO&]E+O$[Y_[1@X5I_P`6BE2YMW9)*]GWT\M-.I_2%117,>*?
M&/A+P59P:CXQ\3^'O"FG7%P+2#4/$FMZ;H5E+=LC2):Q76J7-M!)<R)'(Z0(
MYD9(Y'`VHU?JTYQA%RG)1BMY-V2^9P'3T5QWA;XA>!O'(O?^$,\9^$O%G]FF
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M7-M"2<'@/G(X[X\0_P"&QOV3OM?V/_AI+X&"YW;/*_X6KX)W^9_SS`_M?&[/
M;(KFJXS"49<M;$X>E+;EJUJ=-Z6O;GE%NUU>R\G9L:C-[1;^3[K]+_\`#7/I
MBBN4\*>-_!OC:T;4/!OBKPWXJL01F\\-Z]I>NVP],SZ7<W4(X(Q\^><'MGJZ
MVA4A4BITY1G![2BU)/OJNP@HHS7(^+/'?@OP-9+J/C3Q7X:\)Z><G[;XEU[2
M]!M>.N)]3N;6)N,X`;)Q^1.I"G%SJ2C"$=Y2=DO4#KJ*^95_;)_9,>X^RK^T
MI\##<%B@C'Q4\%`^8,?(/^)O@MSST`KW#PMXV\'>-K#^U/!WBCPYXJTXGB^\
M-ZYIFN6A]/\`2=,NKJ'/."-^0<\>N%+'8.O+DHXK#U9/[-*M3J/INH2E9]D]
M[.P^6:7O1:^3[+]7_3.JHHS_`(T5U""BN)\3_$?P!X(EM+?QGXW\'>$)[^.6
M:PA\3^)]%T"6]B@9$GDM(]6O+1[E(7D1)FA5UB:1%<JS`5T>CZQIFOZ=::QH
MNH:?J^DZA!'=:?JFE7MOJ&G7]M+DQW%G>VCRVUS`ZX*30RR(W.#QDY0K0FW!
M3@ZD4G.$9*3C?:ZT?X>0&G1116H!17DVK?'CX*^'M4OM#\1?%SX8Z!K6F3_9
MM0T?6?'OA73-4L;C8DGD7NGWVJ6]W:S>7)')Y<T2/LD1P-K`GTRPU"SU.TM[
M^PNK:]L;R"&ZM+RTN(KFUNK:X198+BWN(6:*:":)TDAFB9HY8W5T=E8&LJ=>
MC5<HTZL)RC;F49)N-^Z6J`NT45R/BKQ]X(\#QV4OC/QAX6\)Q:B\T=C+XG\0
MZ1H$5Y)`BR3):R:K=VJW+Q1NKR)"9'16#,H4YIU:L*,'4J24(1WD]$OF!UU%
M<QX5\8^$_&MC-J?@[Q-X>\5:;!<&TFU#PWK>G:[917:QI,]I-=:9<7$$5U'%
M-#*]N[B58YHW*[74G+\2_$[X<^"[J"P\8^/?!?A&]N[?[79VGB7Q5H6@W5U:
M^;)`;JWM]5OK.6:W$T4D1FB5T$B.A8,I%3*O2A%5)5*<:37\24TETM;H_O0:
MO1*[.[HKR+_A?_P+_P"BS_";_P`./X/_`/EQ1_PO_P"!?_19_A-_X<?P?_\`
M+BL_KV#_`.@FC_X,C_F.S[/[CUVBO(O^%_\`P*_Z+/\`"?\`#XC>#OZZR*]2
MLKVWU"V@O;.>"ZL[J&&YM;JVF2XM[FWGC66&XMYXR8IH9HG22*6-FCD1@R,R
MD$ZTJ]&M?V-6%3EMS<DE*U]KV[A9K=-?(MT5C:_XAT/PKI-YKWB36-*T#1-.
MB$VH:QK>H6FE:781-)'"LMYJ%]+!:6L332QQ"2>:-#))'&"7=0</P?\`$?X?
M_$!;]O`WCGPAXS72C;KJ;>%/$FC>(1IYNUE:U%\='O;P6IN5@F:W\\Q^>L,A
MC#!&P2K4XU(4I5*:J33<8.24Y6M=QCO)*^OJA:[VT.UHHHK4`HK$U[Q)X?\`
M"]A)JGB37-&\/Z;"K--J&N:I9:38Q!<$F2[OY[>!`!DDM(``.OKX'/\`MB?L
MGVUVUE<?M)?`Z&Y1_+:%_BGX+#I(.J./[7PK#TR<^V.>>MB\-0:5;$4*+E>R
MJUJ=-NS2=E.2;M=7MMI?<:C-_#%M>C[K_@_U<^EZ*X?P?\2_A[\0(&N?`_CK
MP?XQ@54=IO"WB71M?1%=2Z[VTJ\N@GRC/S$''7!S7<5I2JTZT%.E.%2+^U3D
MIQ?HT(**,UX5XU_::_9X^&EX^G_$#XW_``H\'7\>_P`[3_$/C[POI=_&4P6#
MV-SJ,5VK`'A&A#MV7M45\31PRYJU6E2CUE5JTZ45MNYRCWZ?Y#LWLG]Q[K17
MRKI?[<7['VM3K;:9^TW\#;J=F"+&OQ+\*1LSE@JHOG:K'N8L0!MSCOC(KZ*\
M.^*_#/BZQ34_"WB'0_$>G2*K)?Z#J^GZQ9.&S@I=:=<7$#`X."'P>Q-10QV$
MQ+DL/BL/6<;<RI5Z55KFO:ZA)M7L[7WMH.4)Q^*+7JOZ[G04445U$A7SG^UU
MK5UX<_94_:6\0V3%+S0?V?OC)K-JZL4=;C3?ASXBO("C`AE(EA4[E(96VD$5
M]&5\\_M9Z#=^*?V6_P!I#PQ8QO)>^(_@)\8-"M(XU+2/<ZK\._$-C;HBCDN9
M9P%4<LQ`QS7#F7M/J.+]E_%^JXGDWW]A.UO.]C2E_%I_]?(?^E(_F`_X-YM`
MM;[]J/XP^(95!NM$^!EUI]HQ`+1#7O''A%KB6/(.U]FD)%O&"$E=<D.5/]@M
M?QY?\&]7B6UT_P#:I^+7AN9U2X\0_`R_O;(,5'G2^'_&WA`RVZ$D9D,&J23[
M0?\`5V\KGY48C^PVOB?"]TWPI0]G_P!!>-YEV?UB=K^?Z6.G,/\`>);[+>^U
MEW_'T"BBBOT0X@HHHH`****`"BBB@#P3]J+PY;^+_P!FSX_>%KJ/S8/$'P5^
M*6D.FS>W_$P\$:S;J\:X/[Z.219(&&62549<$!E_EC_X-[M<FM/VMOBEX>#9
MM==^`6MW<L9=E#7&B>//`1MI0HX9HX]2NE#-RJRN!P[5_4G^U=XGMO!?[,/[
M0WBR[D$</A_X)?%+5.7V&2:T\#ZT]O;JV1B:YN1%;P#<"9Y8@#D@'^7+_@WL
M\/S7G[5WQ8\3;6%IH'P&U33I91'N5;GQ!X[\$-:Q;\91I(M'O'4!AO2&0G.S
MC\PXIUXXX']E;VOML3[7;^%RU?8_^Y/Z1WX6_P!3Q?;DC]^G_`/[$:_GP_X.
M(21^S3\$<`9/QT(YS_T(/BWZCU[?I7]!]?SW_P#!Q'_R;3\$.W_%]#^7_"`^
M+>_^<=:]_CYVX2SI_P#4*O\`T_1,,)_O-'_KXC^?OX">)OVFOV*+#X2_MH_#
M!I$\!^.=4\1>%;J8?:KKPKKDWAO5KJVUSX=?$"RC"+"VJV%I%K6B7!D5@LGV
MO2;R+5-(O%MO[5/V,OVS_A1^VM\*[7XA?#R\33]9T];:R\>>`K^YC?Q#X'\0
M/&SR6%_&JQ&[TRY\N2;1=;AA2TU:T5F"V]Y!>V-I^8__``1V^%/P_P#V@_\`
M@F?XH^$?Q3T"T\4^"M;^*_Q&T;5-,NE*2IYEIX8U*SU&PN5)ET[5M,O9X[_2
M]1LC#<V%[!;W4#B5-[?D-\<?@5^TY_P1S_:3T7XK?"S5]1UCX8ZKJ4]KX2\8
MW%M-+X=\9>&YWDNK_P"&7Q0L+5XK>'5X[6+=(JF!;U[6'Q/X8FM-3M&@T?\`
M/LCK9GP=EV5YQ257&\,9EA,-B,RPZ?-6R[$U*<85*])-/F4W&\HKE4N5)M<I
MVUU#%3J0ERPQ5.;A%REIR*R271N*TUMNC]+O^#C*WD?X7?LRW0C4I#X_\>V[
M2'!9&N?#NBRQJ%X9@_V1F95ZF-03R*^X/^")AS_P3K^#QX_Y&/XK@8Z<?$[Q
M9W_'GBOR-_X*K_M9?#7]MO\`8?\`V=?C+\/)C9ZCH/QFG\.^/_!EU<)-K'@7
MQ1J_@#6M0.E:DJK%]HT^];1)YM`UL116NJV,;R+';7L%_I]C^N7_``1,_P"4
M=?P>QW\2?%G''_53O%G^3[UZ^3XJCC?$K'XO#58UL/B>'J%>A.#O"5*I+`<D
MEYNTDXO:U]-C*M"4,#&$E:4<0HM?X?\`AS]8Z_GD_P""K7_!6?Q'\`?$NH?L
MX_LY36-O\4;&SB_X6'\0[F"'4XO`S:I9I>6?A_PS8W"R6=SXI^Q36UYJ&IZA
M!<V&C)=6UM#:W6JFY73?Z&Z_SY_VT=&U?P!_P4)^/'_"SK:YEC@_:-U[Q7J<
M=W')*VJ>#]=\8/XLT:ZAB=09K#4_"&J6;VL$6(#;R+:1[5!">MXD9QC\JRC#
M0P-5X5YCB_J=?&17OX>BZ<IR=*7_`"[JSY>6$_LV;LW:V>"I0JU7[17C&$I<
MO>UM#]O_`-F'_@CKXF_:%T31OCI^W_\`%SXI^+?&'B^RL_$%I\/(_$MVVH:7
MIFJ(M[:VWBSQ'K']IW]M?RQRAKKP]H4&FQ:.66S:_>XAEBM_T$G_`."+7_!/
M*;2_[-7X-:G;OL"?VI!\1?B`NJ9'1S/)XCD@9AD_*]LT9)Y3'%?I[H.MZ3XC
MT;2]?T&^L]3T+6M.L=6T?4]/GCN+#4=,U&W2YL;VSGB)BEM;JWDCFMY(V*21
M2(R]:U\CU%>S@>#N'\-AX0G@,/CJLHQE6QF-C]:Q.(J27O5:E:K*;?-T2LEW
M9E/$5G)N-25)/:$':,;=$NG]:'Y=_LS_`/!)/]F7]EGXMO\`%_P!J_Q/U35[
M6"2+P]HOB7Q:D^@Z!-,K13WBVVCZ?HTVMS&!W@MXO$$VIV5LKF9+4W:6]Q!^
MHM&:*]W`9;@LKHO#X##4L+0<G/V5&"A!2?Q.R[F4IRG)RF^:3W=NVVWD?A/_
M`,%>_P#@ICXD_92M]$^!OP1FL[7XS>,O#_\`PD.M>+;B&*_'P[\)7MW/I]E+
MIUC/'+9W/BG6YK/4'L3J,<EOH^GVG]H26=S/?:>4^3OV(O\`@E%-^U_X"\/_
M`+4?[;7Q3^*'C6]^)$!\2^%/""^)KL:C=>&;V1GTW6?$WB74UU#4(TUN(?;]
M+T?0!IJ66D3V,CWQEG:TM?@O_@N5X8\1Z)^WSXMUK6()UTCQEX`^'&M>$[AU
M?R)M)L/#T/AB^BMV(V?N/$.B:L9(E8LC7",P'G(6_J]_8&\8:'XY_8O_`&9=
M>\.S03::OP2^'6A.+=T9+?5O"OARR\+:_8OY8"K/8:[HVI6ERF`5GAE!`Q7Y
M;E\/]9N-\]PF=RE6P>4*4<#EKE4CA)\LZ</;UJ4)P56JE)-RFGS=$K,]&K%8
M?!T*E)VJ5N5RJ+XE?5*+UM;7IKY/?YPD_P"",'_!/"2P%A_PI*^0A#']N3XB
M_$,7_0KO$Q\4&,.,YRL`![KTQ^4G[<W_``2[\2?L/>#=3_:G_8E^*WQ0\-:?
MX$>WU+QIX5_X2.XCU_1-%DN8H/[>T37]*73Y=6TC2[B>`:QH^N6]T\.E//J,
ME]>6]I=6K_U4Y'3(S7R=^W9J>BZ3^QC^U'=^();6/2S\`_BK9R&Z*B*2ZU'P
M9JVGZ7;*&8+)<76JW5E;6L993)<S1*OS$5];G?"N13RW&3HX##X'$4,+B*V'
MQ>"A]4KX>K3I<\:D*E!TGHX)6DWOI;5/GH8FLJL%.I*I&4HQ<9N\7=I:I[VU
M:/S9_P""1?\`P4W\2_M7-J_P+^-_V*7XQ^%/#I\0Z'XOM((K"/XA^&M.N;73
M]1_M&P@2.SM/%>D2WEK<W@TV.*SU73IY-0BL[22QO]_[L5_#A_P1`TG6=2_X
M*#_#N\TM)C9:%X*^)VJ>(7C4LD>D2^$+_18?M!Z+#)KVK:+""Q`\^2%0"Q7'
M]Q]<GAQFV-S?AU5L?4]M6PV*J815FO?K4Z=.C.,ZC^U4_>.,IWO)QOH5CZ,*
M-?EIZ1<(RMVOT_#R/Y)_^#BG_DMW[.__`&2OQ)_ZEK5^]?\`P3(_Y,'_`&6O
M^R5:1_Z5W]?@I_P<4_\`);OV=_\`LEGB3_U+3^5?O5_P3(./V!_V6N0/^+5:
M1U_Z^K^O'R!_\;'XL_[!8_\`I."*KO\`V"A_U\7Y(^[J**`<].?I7ZK==U_7
M_#G`?C-_P4]_X)<>&?VN]"NOBI\*[73_``U^T=H6GL(KC$5EI'Q2T^RC'D>'
MO$\FWR;;6[>%?)\.^)7_`'D#B'3]8>;25BFTS\D?^":W_!2SQK^QYXS;]E']
MJ^+7=.^&>FZ]<^&[*]\1P7:>(O@AXA%W):SV%_!.&NI/`YNG/VVSC#R:"[S:
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M3O\`P6@_:9U7XD_$C5+_`,,_"/PS?166OZ]:12GPO\/?#(F%U:?#WX<V=T#;
MZCXHOK8I+//,&=?M`\1>(GD!LK&^^6?V+?@CXZ_;^^/WPI^`?C3XF^(8/!?@
M7PIJLR7.H7UQJMSX5^&_A^];5=1\.^#+2[>2ULKK4;_5([2R#(;6R-T;Z6&:
MUTRWL5_NT^#OP<^'7P$^'OA[X6_"OPU8^%?!7ABS6TTS2[)/G=R2]UJ&HW39
MGU+5M2N&DO-3U2\>6\O[R:6XN)7=LUXN`ECO$>K#%8Z+P/#6!JQC_9\*T:E7
M'XZG"E.<,3*FUS48.=G!QL^:Z:=TKJ*.!O"*YJ\HRC.;TLGRVM&S3M9]5KWU
M*7P/^!_PW_9V^''AWX4_"CP[:>&O!WANS2WM+2!%-U?7>!]LUG6+W`FU36M4
MD'VC4M2NF>>YG)8E8Q'%'\R_M3_\$W_V9?VQ?&>@_$#XU:1XKO?$WAOPU'X2
MTZZ\.^++_P`/V_\`8D6JZCK,4-Q:P)-!--'?ZMJ$J7`1)2EQY4A=(H1'][45
M^HU\KP&*PD<#B,)0JX2'L^3#SIITH^ROR6A_=N^OXZG!&4H24X-QDMFMUW/Y
MW?VP/^".7[%WP:_9>^.WQ4\#:+\0K/QAX`^&GB7Q7X=N+_QY>ZE91:KHUB]W
M:-<V5Q:>5<PL\8CFB8J6A=T5T+;J_)K_`()"_L8?!7]L[XG?%OPS\;+3Q'>Z
M/X+\"Z1KNC0^'==FT&4:EJ.OII\DMS<6\,LLT:6RLJ0AHUS(S$DA=O\`5M_P
M43_Y,5_:L[_\60\=]O\`J"S_`%_SZ5_/U_P;JG_B]G[1`X_Y)=X8_P#4M^HR
M/ZG-?DN>9'E%'CGAC`TLOPM+"8JE7]OAZ=/EI5=,4Y.4%9.[\E;\#T\/6K/!
M8ANI)RC.$8.6MM$VTM%=W]-#]1%_X(5?L!*?^1<^)V,C<I^).J`,`0=K8M@P
M!QSM*MZ$5^N_ASP]I?A30M&\-:%;)8Z)X?TK3]$T>QBW&.RTO2[2&QL+2-G9
MW:.VM8(H8R[%MB#<Q/-;=%?JN!R7*LLE4GE^!P^$E5BHU'0IJ#G%;*5K7MJU
MV;9YTZM2I;VDY3MM=WM>W^2/S-_X+#?\HX/VD.W^@_#/\?\`B\GP[X_^M_\`
MKK\F/^#<4DZ]^UKP,C2_@K_Z5?$T>G'Y5^L__!8;_E'!^TAG_GQ^&?;I_P`7
ME^'7^>W]#^2W_!N)G^WOVMO^P7\%>>W_`!]_$WMW_/WK\]SAO_B*'#VNG]ES
M>KLM\9M_7?J=M#_<<1_U]A_[8?U-U^)/_!5G_@J'/^Q\FF_!WX/VVE:O\=O$
MNBC7;O5=40:AH_PV\.WIFAT_4[K3@0FI>)-5FM;F31]+NB+.TM+<:KJ<-W!/
M86&H_MM7\(G_``63\,^*_#__``4'^-=]XGANQ:^*X/`OB/PI>W`D\B_\,'P/
MX?T.V:P:0`-;6&IZ+JFCLL:JB76GW"89]SO['B+G./R7(8U<NYH5L5BJ>%EB
M(Z/#TYPJ3E4C+[%1\EH3L^7WFE>QG@:,*U?EJ:Q4)2L[ZM6TT:[GZ-_LD?\`
M!,WXN?M[>&M%_:<_;H^./Q2U70/&L?\`;?@CP3!K+?V]JGAVYE,EEK=W<ZG#
M>:1X/T/58P;G1=$T#1$FFTJ6TOQ<:?#<10M^I5M_P19_X)Y6^F?V<_P;U2[D
MV;#JEW\1?B"^J<@;I%GC\20P)(S#=\ELJ*20L87BOM']E3Q/X8\8_LU?`CQ#
MX-NK*Z\-7_PC^'O]E-8&(P6\-KX5TZRDL&2%BMM<Z=<6T^GW=DP6:RNK:6TG
M1)H70?0FX>H_,5V91PGD$<!AJE7"T,SK5\/0JUL;C.;&5L14G3C4E4=2K.>C
M<K))1^%<UWHL:E>M[22C4E3C=6A!VC%>2Z/3TO\`C^2?PB_X(R?LE?!7XQZ#
M\8?!M_\`%;S_``U.-0T?PAJ7C9W\.V^KQR;[2^N+C3=.TW7]0ALW"R1:;?:Q
M<6,[JHU"*]@W0-^MM&:*^CR_+,ORNG.EE^%HX6G4J.K.%&*C%REULM%MI;0S
MG5J5+>TFY\NBOTO:_P!]C^9G_@NY^U3^T5\,O$/P\^"7P]U+Q-X`^%?C#P5/
MXC\1>,_#TEWI=UXXUR74]8TV]\%_\)%9M'-:6&A:;8V6I:II=G/:3ZDVNP?V
MAYNGK;I+S'_!,C_@GQ_P3X^/?P9\,?$'XC^,HOC1\7M;BNKSQEX%O?'ESX;;
MP1?-?W,2:-+X6T;4=*\0W3-;)!,VMZE>75CJS3?;-*$5JXW?T?\`Q:^#?PQ^
M.O@^]\!?%GP7X?\`'?A'4`3/H_B"PBO88YPI6*]L9CMNM,U&VR7M=2TZ>UO[
M5QNM[B-B37X>?%C_`(-^_@OK&NW'B'X%_&?QW\('DD>>WT+4K"#QOIVG2,Q?
MR]*U(:EX?\0V]LF1L2_U/5+@$*?M9&17YSG'#6;0X@JY['"8;B;"58N%+*\;
M7C1E@(SY;_5H5%6H5G%Q3ESTO>]VW)9M]=*M3]BJ3E.ARNW-!N7/>WQ)6M:V
M]WN]NOUWXI_X(N_\$]?$U@UI:_!_4_"DY5U34O"_C_QQ;7T3,"`ZKJNNZO8R
M%<L52ZLKB(G!>-]HQB_LQ_\`!'_X)?LL_&RW^,'@KXH?&'5K?2[>8Z-X(U;Q
M%!8:-'J<X,27VN7/AJ#1)/$]K:V[-':Z3JMNU@9=D]]'?F&!(_SCU7_@F-_P
M52^`=B^K?L]?MAZEXUM],0W%IX9A^(/C+PK=W<<.7^SP:!XLGU;P?<R2!0?L
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M"M^S#K$_[!'_``51TGPUXFN#I?A_P;\9O%/P>\275X3!;2>"_&5QJ7AG2-?N
MV8J!IZ6&K>&O&*2.^U;2*"5F#\#^Z@$$9!!!Y!'(YY'YCFOY._\`@OK^RA>>
M'?'?@W]K;PKISMHGC>VL/`/Q.FM8FQ8>+M"MW7PEXAO&B!8)K_AVV70O.+H+
M>Z\+Z9&7,NI1U^O/_!*#]M"Q_:S_`&:]&LO$&J13?&+X26>E^"OB19S3*;[5
M(;2T-MX8\<>63YKV_BG3+,M?7!15'B&SUM?+BA,`/Y1P;7CP[G>=\(XCW8O%
MU,PRF[LJM&K\5&,FESU=(.$=+KF[:^AB8^VI4L3%\SY5"JU]FUE!]];RUMZ7
M/U,HHS17ZN>>%%%%`!1110`445#//';1//-)'%#$CRRRRN(XXHHD,DDDDC85
M$1%9F9B``,D@9-#=M].NO9;OY`?CQ_P7!^.5E\*_V)?$'@FVO4@\3_'+Q%HO
M@#2K=)=ES_8EG>0>)_&%[Y:D,]D-'T==!N^B--XALX'($_/R_P#\&\_P=N-"
M^#OQL^-^I6C1/\1?&6B>"?#\LT6'ET3X?Z?>7VHWMNS$EX+W6O%LNGS,25,W
MA\QX_<[F_)[_`(*3?M(>(/\`@H3^V=H'PZ^#4<WB7P?X7UFV^$'P>L+)FEM?
M%.O:OJUO;:_XQ@8;DCM?$&K^1%;WK")8_"N@:;J-SY8>ZA7^PO\`9>^!6@_L
MT_`;X9?`_P`.LLUEX"\,6.EWFH+'Y0UC7[AI=3\4:X8^J/K?B2^U356C8EH1
M=B#(2-57\HR>HN)>.<9GD'SY7D%)X'"UDKPJ8J;5-<FRTE4KU6];.48^9WU+
M4,)&A)MU:MJKCLDG9VOKV71:>6_T'7XJ_P#!;C]GGXT?M%?`/X3^'?@I\/\`
M6OB)KF@?%U-<UC2]#-E]KL-'?P=XET_[>\5Y=6WF0+>7=M;L(2[*\\>Y0#FO
MVJHK]#SG*Z.=9=BLLQ%6=*CBZ7LYRIJ'/I.$TX\\9;.&RMOOHCDI5'2G&:5W
M'IL?D?\`\$8?@C\8/@!^RAXA\"_&GP)K7P]\3S_&3Q9X@L-%UUK$WDVAZAX:
M\%6=M?JMC=WBI#->Z9J$*"5XY";=G\L(RY_2;XN_"+X??'7X?^(OA?\`%'PY
M8^*O!7BFQ>RU;2;U.IRLEM?65PN)[#4].N$CO-,U*T>*\T^]AANK6:.:)'7T
MK-%+`Y3AL#E6&RE+V^%P^&CA>6NN=5*225IIO6]M-=.@IS<ZDZEDN>7-;HKV
M^_8_B4_:D_X(Y_M:?"#XC:_X5^!GA#Q5\;/@]KMU%K>@:OH%QIT=Y##:'4$T
MS2_&ND37UBG_``D>@I>SVUKJD%O)8:A:7,][8-9W%[?V5G_27_P2B^$WQ(^"
M'[$'PO\`AQ\5O">H^"?&VD:M\1;S4_#>K-:M?V,.L^/_`!+JNGM<?8Y[F!?M
M-A=VUU&@EWK',@D2-^*_2"BO`R3@?*\@S7$9GE]7$Q]O2J45A:D_:4*%.=2E
M4]G1<KU/9KV2483G-1NVFKM/:IB9U:4:<HQM%IW2LW9:72T"OR\_X*`_\$Q/
MA5^V]IMCXB;4W^'OQIT#2SIF@?$/3[%+RVU/3H6EFM=!\8Z2LD#:KI5O//*U
ME=VUQ;:MI9ED^S74ELTMG)^H=%?2YCEN#S;#3P6/HPQ&&J+WZ4XIVE]FI![P
MJ0UY)K579A"<Z<E.#Y9+9_UZ'\OWPC^'_P#P68_X)\6@\">#/`OA[]I?X-:7
M,_\`8V@VNL0^)K#2[1Y'(7PW%/J7AKQYX>CDV^:VCK:7VBV<\CR06DC$R-]2
MV'_!2;_@H5>J=+C_`."6OQ(.OJBH\LFM^)+#1C*6!#"6\\%1(L6"7(.H;E^Z
M7?;NK]W**^=PW"F(RZG[#+N)<ZPN$3_=X:K'+L="A'2U.C4QN"K5:=.-O=AS
MNW?16V==2UG2@Y]91O&^WQ)7OM_PY^1'P`^*W_!6'Q_\6]!U?XP?LZ_!7X5_
M`^<FU\1>'K[Q68_&<%A/+&RZUI-[INK>+KR\UG3HV9ETK4-)TK3;_?-:7#:=
M,8;R#]=Z**^@RW`U,!1E2JYCCLQE*;G[7'3HSG!RM>%/V5&ERTT_A@^;EOH]
M=<IR4K6A&%OY5:^V_I8^%_VY/V$/A1^V_P##RR\*^-FN?#WC'PR;V[^'_P`1
M='MH9=:\,7MY"(KJUG@D,<>L:!J*QP)JFC3S0"811W-I=65[##=)^,/P3^#/
M_!6?_@F?+K7@WX8?#KPQ^T]\#;_5YM8BT'2-3^VPVMS-L2;4='TN:_T7QCX8
MU+4(HXCJ-C;V.OZ$TJ";RKBX5YY/ZAJ*\G,N%<!F&-AFE&MBLLS:"Y?[0P$X
M0JU(:7IXB%2%2E7I.RO"I%I=&KN^D*\X15-J,Z:=U":NEML[W1^&*_\`!3C]
MN2.'[-<?\$L/C*VKC$9:'5O%']G?:3GGS#\.)/W(;:"XN&4Y)#\&OD_X\^"?
M^"NW_!2.SMOAMXG^"WA_]F3X(7&IVM]JVF:_K4>EIJ1L;F.YLG\4W$UYJ?C3
MQ%'ITN+VRT[3/#FF:1+J4%I=7%IYELEQ!_3]FBN?$<+8G'4987,N(\VQ6#J.
M/ML-"&!P4:\5_P`NZU3"X:G5E3E]J"G%/0<:ZA)3ITH*2V<KSMMLGHMOZZ_G
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M_#<G_!8#_I&]HW_@SUK_`.:NOUN_9C\9_&3X@?!7PCXN^/OP[T[X3_%+6H]7
MN/$'@#2[R6_@\/P1:[J=GHL<T\US>2"]OM$MM.U*[MS<S&TGO9+61EFAEBC^
M@:*]?+<IQN!K2JXC/,QS*+IN$:.+CA?9Q;M[Z=*A3J75K)1G%/K>R2RJ3C-)
M*G"FNO(M[6MO?M^+"O!?VH/#6N^-/V;?C[X,\+:;-J_B;Q;\%OBEX9\/:3`T
M:3:GKNN>!];TW2=/A>=XX4FO=0N;>UB,TL46^10TB9S7O.1ZBEKUZ]&&(HU:
M%3X*M*I2G;27+5@X.SO[K]ZZWO:QFG:2EVZ?-/\`0_E%_P""/'[$O[5?P$_:
M^_X6!\8?@EXM\`>#X/A;XUTEM>UXZ7':-J6HW6@?8[&,6NHW4[W%PL$[J!"5
M6.&1W90!G^KJBBO'X=X?PO#67_V=@ZM:K1]O4K\U?D<^:IRWUA"-_A5V[W\C
M:O7E7GSRT?+&-O3_`#"BBBO>,3Y4_;?\&>*OB-^R+^T1X"\$:)=>(_%_B[X2
M>,M#\.:'8M"MYJNK7NDS1V=A;&XD@@\ZYE811^;-&ID9%+9;-?B]_P`$0_V2
M?VDOV</BG\<?$'QN^$?B?X<Z3X@^'_AW2=$O-?\`[.5-3U&W\127L]M:+9WU
MW,\L-NF]R8UC4.NZ169$?^DRBOGL;PYA,=GF6Y].MB*>)RRG.E2IP</93C/V
ME^92C)IKVEURVVUO?3:-:<*,Z,=%.7,WK?II^'^04445]"8GP/\`\%.OAEX^
M^,?[#7QS^&WPP\,WWC#QQXEL?`PT3PYIAMUO]3.D?$[P3KM^EN;J:"$O!I>F
MWUTRO*I,<#!-TA2-_P`W?^"&W[*W[0G[-NI_M(WOQP^%WB+X<0>+[+X56OAM
MO$']GH^L3:++X]EU46D5E>WC[+'^UM/\^63RU!G"KN*N%_H:HKYS$\-87%9_
M@>(9U\1'%8##2PU*E!P]C*$O;7<E*,K/]\]DOAWUTV5:4:,Z*T4Y<S?HE96^
M7XA7P3^W3^P%\(_VX_!%CH_C5[CPSX[\,17+^`_B3HUM!/K&@27"9N=,O[24
MQ1:]X;OY`DE[HMS-`5D7[7I]Y879>=_O:C.>E>OCL#A<RPU7!XVE"OAJT7"K
M3J1334M%*+^Q4C]B:UBWH9PG*G)3@^64=G;8_EH^%_[,W_!7O_@G%>ZCI'P&
MMO#/[0WP<?4)]1/@ZUU*UU/1)S)++)+>VGA77=4\.>+/"^L78.Z]A\)WUW:7
M<[K+=-J<L9>OK+2O^"D__!0^%8])U?\`X);?$:Z\0E=CSZ9J?BJRT>290!N7
M[1X,U&.")I2VU/[6N0B?>N&X)_>6BOFL-PE5RZG]7RGB/.\!@T_W>$E_9^-I
M4(K:G0EC<%6JTZ:Z1YVC?V\9:U*%*<GO+WX7U3U4))=.M_*Q^+7PZ^-__!8/
MXE?$3PIK&H_LI?!OX2?"J#4TD\2^'_''C#R-?U719ABYB76;/5]?UC3M2M$;
M[19O!X,CBDO+=([RTDMG;'[2T45[V6Y?5P$:RJYEC\RE6J*HYXZ=&;I.VL**
MHT:7)3=](/F2LK-:WRJ5%.UJ<8)7^&^M[;]]C\<?VR/$W_!7+PY\6Y/$'[*7
M@KX7>)?@KI-C;6EAX76Y\.:OXFU^X,:7.H:QXG@\4R^%M1L[AIM]EI^F^%=8
ME@@LTCDEN+FZF?R_GK1O^"CW_!4'P@8['XG?\$V/$?B6XB15EO\`P5IGCG2H
MIF4!7<)#9>.K)C(,,HBNXHP&.`=G/]"=%>37X>QTL37Q.$XESC"2KS]HZ3>%
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MC*-&$://\4H?&[;6F]5;\=F(JA!A0`.``!@`````=@```.U.HHK[(Y0HHHH`
M\I^-OP:\#_M`_"_QG\(?B1IHU7P;XXT.[T75K8!%NK=Y3'-8:OIMPZ2?9-8T
M2_@MM5TB\"-]EU&UMK@I)Y06OXE-3T_]HW_@C[^V6EQ;J]Y;V$T[:==7,5Q9
M^$/C3\)KV^622VF(:95E,-K']K@5YK[PGXLL$GB2XAL[6\OO[P:^4OVM_P!C
M_P"$7[9'PPNOAO\`%/3',D'GWO@_QCIB11>*/`VO/%LBU?0;QHV/E.PCCU/3
M+CS;#5K4"&[A:2.VN+?XGB[A>IG-/#X[+JWU/.LME[7`XF%X.HUR_N*TT[N,
MN5<LK/EU]UW.K"UXT9RC45Z56/)4UMUT?RNRU^R=^UQ\(OVPOA=8?$SX5:S#
M*/+MK?Q3X2O9X5\4>"->DBWSZ)XAL5;?"ZE7:POXU:PU:U`N[&9T\Q(OJ.OX
M3OBO\`OVV_\`@DI\98?'WA76=:TWP^;PV?AWXM^%+2YO/A]XYTEIA-%X?\::
M1<?:=/M+JZC@@%]X3\2HQ:[C:XT&_OS;6NIK^UO[)W_!>;X(_$*RTSPS^TWH
M=Q\&O&K+#;W'C+1[74-?^&FL7)"1B[,5I'>>)?"QNIGP+6[L]8T^V!WW&N1P
MCY/-R3C[#N3RKB:$LGSG#R=*H\2O9X3$.*5ZBKM*E2OH^64K/F]UNSM=;`N-
MZF'<:M*6L8P=W%*V^E^J[]?5_P!`E%>;_#CXO_"WXNZ2NN?##XB^"?B#I+)'
M*+_P=XFT?Q##&DJAD%R-,NKA[27!&Z&Y6*9&^5T4\5Z/D>HK]#HUJ=>"J4JE
M.K![3IR4HOT:.+7L+14<LT4$;RS21PQ1HTDDDKK''&B@EG=W(5$4`EF8@``D
MG%?!?[0/_!2[]CC]F^POO^$U^,?AOQ!XCM%E6+P/\.[RW\<^*[BXBW`VDUKH
MDTVG:)*2C_-XDU+1H!L=3+Y@$;8XO'X/`4W6QF*P^%HQOS5*]:%)*UM$I-.3
MUV5VNNY4(3J2481<I/9*_P"=NF_IJ?>Y(`))``Y)/``]23P*_E]_X*[_`/!5
MC2[W2_$W[*/[-GB&#4#?I<Z)\8OB?HEX);)+$N]MJ7P_\'ZA:OY=W-=X:P\6
MZY;S&U2R>ZT*Q:[DO+XV_P`:?MC_`/!7S]H?]L&\E^#GP%\.Z[\+_AUXIO!H
M<'ASPHU[K7Q5^(<=Y(;:/3-5U'1HC<P6NJ(XBF\*>&(LW,;W-IJFJ:M:.57[
MG_X)J?\`!&&;PWJ&A?'C]L/1K>76;)[36?!/P0N_)OK/2KQ62YM=:^)#*TUK
M?W]M(!-9^$K=I;:WF*3>(I9[SS='L?R_->),QXNJO(^$HU(86?\`R,,]E>&'
MI8>Z4X4II-WE9JZ=Y)674[Z>'AATJV*=G=>SI)7E/:]KVO:ZO=;.YUG_``1/
M_P""=-]\.K"W_:[^-&B26'C7Q'I,D/P:\+ZG:;+[POX6UFU*7OCC4;>8;[37
M/%&G3&ST.`JDMAX;N;JYG\XZ\L-E_1W444*0J$0`*JA5``4*JD[5`7"@*#@`
M`<`9R>:EK]!R#(\)P]EE#+<&DZ=-<]6I:TZ]>:7M:\]7K-I:7=E;5G%5JRK3
ME.772*_EBMHWZV[V7H%?G?\`M_?MPZM^Q=IOP7DT/X>:/X_U+XQ>/9O`T"^(
M/%\G@S1]`=+>QD35-2U6+1-;"V2RW\7VR>2&-+.TCFN<RL@A?]$*_+7_`(*;
M_L8_$[]L+2_@%#\-9OAU)+\)OB3=>,]?T/XEWNL6.@^)=*:WTU1HLATG0M>:
M:"^DLOLNH0W-JL36$\^QGDVQ/'$<LRAE.)GE*G+'Q=%4(P4')WQ%%5;*I&:U
MI<\-M%-O=(='V?M8^V7[O[7?I;_,P/C5^W]\9_V=_!-]X]^(GPY_94\0:9I>
MR6Y\-_#W]KW[5XYU.%KB&$Q^&?#?B;X2:&WB+4567>NF:?<RW<XCE,2$(-WZ
M%?`?XLK\<OA)X%^*R>#?%?@!?'&@6NO1^$?&]BFG>)='CNGG2.+4+6*691'<
MI"+[3Y\QF\TNZL;UH+<W'D)^87Q._8T^,OQ&\%^(/">F_L?_`/!.?P%JNLZ5
M>:?IOC:UF\4ZGJ_A>YN56--;T2'2/@WX6OUUC36'VO2IX-<L/LNH16MT6ECA
M>WG^WOV(OV>_'G[,7P)T?X4_$;XPZ_\`&SQ'8:GJ.J/XFUQ;M8=(M-16U\GP
MGH!U*[U#5&\/:0]O-)8MJ-[/<&2]N3%'96?V6PM?+RJIG:S*<<1#$SRVI@U)
M59TZ%.-'$1M9N?)0KU?:IO2G1FJ?)[_*IKFNI&GRWA)W3UC_`.`KN]>]WT/K
MZN2\=^)_^$,\%^+?%HL_[1_X1CPQKWB(6/F^0+PZ)I5WJGV0S!)3#]H%KY0E
M$,WE[M_EMC!ZVN*^(_A^[\6^`O&OA2PDAAO?$_A'Q+X>M)[DR"VM[G6-&O=/
MMYK@Q*\@@CFN4:8QI)((@Q1&(Q7U5=572J*@_P!ZZ514V]/WEER7OUO?\;G.
M?,G[!O[6%S^V;^SWI'QPO?!<'@*XU+Q%XGT"7P];ZU)K\4)\.ZB;$7*ZC+IV
MELRW2XE\HVO[HD@.XP:^T*^!?^";7[,'CO\`9$_9AT/X+_$;5?#>L>*-.\4^
M+]?N;SPI<:E=Z-]G\0:J]S:00W&JZ;I%Y)-#`J?:-]C$BRLR)D*6/WU7#DKQ
MKRO`2S%../EA*+QD9)*7MW'WV[:+T7SML:573=27LE:G?W?2P5^9\W_!0#6O
MB?\`'SXA_LY_LH_"&W^+GB?X02O9_%?X@^,_&X^'?PP\&ZO#J4^D7&BQ7EGX
M?\7>)/$6HV^J6FH:?-'IV@Q)]KTO4Q;O<VUE-<K^F%?DCHO[#7Q>_9L_:8^+
MG[17[)/B;P#K.A_'B[N-5^)_P5^+[Z_HFFQZ_/JU]XB;6/!_CWPOIGB"^TUQ
MK&JZO/;Z=J?AJ_M+*'5;FU#74:V`T_#.I9FI9?\`4556&^M/^TI8:%.>+CAE
M2DX+#QJJ5-^TK*%.HG%M1GS+X;,I^SU4[N6G(MD]?>N_*ZMT/6OBW^TE^V!^
MSYX(UOXI_$3]F[X6^/?A_P"$].GUOQB/@_\`&;7I_&>A>'[!//UC6[70/&OP
MT\/6&NVNDV2RWUU;6FM6UZ;:&1U@V)+)%]/_`+.'[0WP\_:C^$OACXS?"^]N
M;OPGXGBN5BBU"W^QZMI>IZ=>7&GZMHVKV8EG2VU'3KRW>*98I[BVF1HKJRN;
MNQGMKNX^3/COX3_;U_:"^%OC'X/P>#_V>/@EI/Q"\/:KX/\`$WCB#XK>/OBE
MKMEX;U^SDT[7CX;\/6_PI^']FNI7NF7%S9VSZCK?DPK/(6W2F)U]_P#V-OV7
M/"W['WP$\*?`[PMK.H^(XM"DU'5=:\2ZK"EK=Z_XDUV\DU#5]2^PQ/+#IUJ9
M72UT_3DFN&L].MK6*>ZO+D2WD_)@JN92S5J$<7+*7@VY5,=25*HL8G'D5%.G
M3K6DG+VCJ4TKJ')>[:<E#EOS)3OI&.MUI>[LK6^=W?:VOU37EOQ5U7XNZ3X?
MM)_@QX3\">,O%$FJPQ7FG?$/QKK?@;18-%^S7;W-[!J>@^#O&U[<:A'=K8PQ
M6$FEP02V\US.U\DEO%;7/J5%?1U:;JP<54G2DUI.GR\\?1RC)?@9'X^G]O3]
MJX?M9+^QM_PS?\$S\4F\$GQ]_:X^//BW_A"%T'[";L%M3/P<_MS[=N`@-JOA
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M.A7%E9ZW\1OA/\1O`>D7>IO-'IUGJGB_P;K'A_3[K4'MX;BX2RM[W489KQH(
M)IQ;)(8899`D;>WC/:_5L1*C_&CA\0Z*VO5]C-P_%$1UE%=W^J_S/SG_`&>_
M^"A/QM_:.^%>B?%CPK\,_P!EKPGHFO76L6MKHGQ%_:MU/PYXKMWT35+G2;J2
M_P!'M?@OK"VD5Q<VDLUD7O"\]FT%UL5)TS^DWP@\1?$3Q1X336?B9X?\`>'M
M:N[MY=+A^&WCO4OB)X9O_#\MO;R:=J<7B+4_!_@J1[JZE-WOMH-*GM8[=+:6
M+4+AIWCA_'7]F/\`8!^._P"S]\']`^%_B7]F']@GXRZOHM]KUY<>/_&6L^('
M\2:NFLZS>:K!#J,M[\#M8FD.F0W::7:M]N=/L=G`%CB8/G]:_@+9?%#2?"4F
MA?$KP!\)OARNAR6>F>$/#?P<\0ZSKGA:U\-VMC!'##Y.K^#?!B:/+:7"RVUO
MI^GV,]F+..!Q)!(7MT^;X>K9K*GA8YLL?]:^JR==5J4_8^V37-S3ITOJT7LH
MVK3YM;)6-:RIJ;5)W7Z=+/7S^??<]SI"0H+,0``22>``.I)I:AG@CN8I()E#
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M3Y>16M*<K2FM/OU6EGUU/J>BBBOKS`\;_:%^*C_`[X'?%OXQ1Z.GB&3X8_#O
MQAXZCT*2];3DU>3PQH5YJT>GO?K;7;6BW4EJL3SI:W#Q([.D,C*%/A?[)G[:
MWP[_`&D/@!X`^,GB#6?`?PWUGQA:ZU)J7@F\\?:)=76@W6C^)=9\/M;S3WK:
M3=-]JCTJ/4X?/TZUD%M?P?NW7;-+ZY^U#\--<^-'[.OQN^$?AJ[T^Q\0?$KX
M6^./`^C7NKO<1Z7;:KXC\/WVE6,U_):075S'9I<W2/<R06T\D4*NZQ.P"GY9
M_8S_`&`OAG\%/V;OAI\,?C)\*/@AX[^)/AFQUQ?%7BF/P+H'B+^U[W5?%FOZ
MY;2#6?$/ARVU>_\`LFEZE8:<9[R&-PUFT,:""*//S->><K.J,<)&E/*Y994=
M2=9U(4'C?K<(0M4ITZK]KR3ERTW%*2B_>5KFJ5-4I2G\?,N3O%):^;YKK[NE
MR_X)_;XTKQ[^WCXJ_8X\.>&M!U?0?#?PMB^("?%+1?&-MJ\-]J!M?#E[/H:Z
M38V,MF@MX?$"123?VT]PDT#;K0(Q*?HG7Y4_#/\`8)U?X6?\%&_&7[5?@^P^
M&OA+X+:]\'D\$:9X*\)V4FB:O:>(GM?"MK>7KZ#IVB6>@0VER^@7-U+=PZBU
MS.\T(EM_,RQ_5:NS(Y9G*EC?[5@HUEF6*5#E?-!X-<GU=TY64IT[<W+*2BWK
MHK"J>S]SV:_Y=0<]]9M.[\KZ:!1117M&84444`>#_M,?&&;]GWX!_%;XTP:`
MGB>7X:^#-8\5QZ!+?G2X]5DTVW61;-]0%K>M:+*YPTPM9BHSMC9L"LC]DSX[
M2_M,?L[?"WXZ3^'(_"4_Q&T"?69?#<.I-K$>E/!JVI:0T":DUG8/=*[:?YZN
MUG`0)/+*Y0DG[7/PFU_X[?LS_&KX.^%;S3;#Q'\1?A_KOA?1;S6I+J'2;?4=
M1MC';R:A-9VM]=0VOF!5DD@L[ET#;EA?:16'^Q/\%?$W[.G[+'P=^"7C&^T?
M4_$_P]\-W&D:S?Z!-=W&CW%U<:YJVJYL)[ZTL+N6*.+4(XB\]E;,SHY$:J5K
MQ%+,/]8%#V<UE7]E2ESM)4_KT,;!K6]^;V;=DU:VMC3E7L.:_O<ZA;KRM+6]
M^_2S_5?5=%%%>V9GX>^&O^"R^CV_QF^*7A'XL_`_6O`WP5^&_P`8]?\`@MJ?
MQWT77+CQ9H_ASQ/8:[K.D^'9O'>BV^A6MYH.E^)HM#OI(M1M[B\2RNH9;40W
MBV]Q-%];?MA?MX:?^S-H_P"SCXA\+>$])^*N@?M`?$W0_`]CK.G>+(K/3;/1
M-:CLYH/$.D:A8Z;K5KK7VBVO$GLD$MK:21HS/>*"-OF7['O[!?B+X1^+/VY_
M^%X1_#OQ]\.OVIOBG/XPT?PQ;+>ZW;R>'+O7?'^ISV'BO3M9T6QM(;LVWBO2
MT2*QGU.-+FREGBNXVCMV;Y'^+O\`P2'^+\/B_P"&_AGX`?&'2A^S#X1^,_AC
MXQV?PE^*E]KU[JOPQU?2[Z1M<T[X;Z[;:7K,]_H.K:?<W+PZ'JLVG"WU%([F
MYN[R[5M2D_.?;<9T<JJ2]C4Q>*Q6+E"DFL/1Q.7QCF4:,)2C[L:^&Q&#CS^U
MYX5*/M&G3DDF^Q/"NI'3EA#XHZM3NMKKX>7?KOTMK_0C1117Z*KV5^QQGY^_
MM!_M]>$OA#\9O!O[,?PZ\!>(/CC^TGX[ACNM(^&WAS5-+\.:7HFG26%]JR:K
MXU\8ZOYMCH%G_8^F:CK#1V]CJM\FEVC74]K`EQ9FYZH^,OV]X[>'4/\`A1'[
M-5P7,;3>'X_C_P"/(M3MHI"`\?\`:\GP2?39[B#K(5@6&0*WE,W&?%?V@_V#
M/&&L_M1>&_VV?V;?B+H7@;X]:/HJ>'/$?AWX@Z!>>(?AKX_T1-$E\.&#4VTJ
M[M-=\.W\FA26^G3:EIC7IEATO2G@MK2[M[FYO?;[;Q)^WM+:BRN/A!^RY9:B
M$*/X@/QN^)-[I)F4*/M*>'$^"]MJ'DO\S+;-X@5U51&UX=X>ODH5,S>,S".8
MO'4J4,4XY<LNPT:M"6"5O9NK4>&Q526*W]NIN*2Y?9W5[=*]GRP=-PUBG/VF
M\9/=1UNTNDFTWY6/L+2KB_N=/LI=5M+:PU-[.UDU&RLKR74;.TOI(5:[MK2_
MFLM-EOK:"?S(H+N2PLGN8E69[2V9S"FC61H3:LVD::=>CL(M;.GV1UF/27N9
M-+35?LZ#45TR2[CANY+`78E^R/<1QSM`4\U%DW5KU];%MI-]4G^!S!1113`*
M***`.>\4>%?#WC71-1\->+-%TKQ'X=UBTEL=6T/6["TU72=3LYUVS6M_IU_!
M<V=W!(N`T4\+H<#(K\._VF/^"#/[.'Q/NK_Q'\"_$FO?`7Q%?-+<-H=O`WB[
MX<O=$M(?LV@WUY9ZWH*SRORND>(!I=I&,6VB87R9/WEHKQLUX?RG.J7LLSP=
M'$Q4>6$W!1KPCI=0K*\E>RVL:4ZM2E)2IRY>ZW3[?<?Q3>,_^")/_!0;X2ZJ
M^H_#&'PI\0/LLCRV&L?#;XB1^%]7C`95C=K7Q?)X+N+:[*;7*VVH7ZQ*-J2R
MO&&',Q_L_?\`!:[P\O\`9=I9_MBV\4&%6+2OBGXGN[)%`"J(9].\:W%DZ\$_
MN9"1GYB<K7]O]%?'2\,,IC98/-<\P--?\NJ&-3IZ6V52G*VSVMOK>R.E8VIU
MA3EZP7Z'\/,_[`/_``5V^.'EV7C7PG\:-:L)6'G3?%GXQ6$5C&KD$--I_B?Q
MQ-?-CYLF+3KJ50B[HV5]I^MO@C_P;U_%?5KNTU+]H'XQ^%O!FEEUFNM`^&UI
M>^,/$4Z%ED-L^M:Q::'HFE7&1(3<V]CXFCW,2(Y,B5?ZT**O"^&'#]*HJN-K
M9CFDE\4,;B(NC/\`Q0I4J<[>4:D5O>X?7JJ^!0I]/<5K[;_UU9\5_LO?\$_O
MV8/V1+*,_"3P!;KXJ:W^SZA\1O$\J>(?'VI(Z;)U?7+N%4TJUN>6N-,\.VFC
M:7*Y,CV1E>1V^U***^]P>"PF7T(8;!8>EAJ$/@I48*$(^B6AR2E*<G*3<I/=
MO=A111742%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
+`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
